Table 1

Data sources and overview of comparative analysis for Harvard and PRIME models

FeatureHarvardPRIME
Model structureProportional outcomesProportional outcomes
Population representationOpen, multi-cohortOpen, multi-cohort
Representation of infectionStaticStatic
Representation of cancer progressionCountry-specific distributions of cancer stages, assuming 2 years lived with disability and 5 years survival for individuals experiencing cancer mortality21Based on Global Burden of Disease-prescribed durations and phases (diagnosis and primary treatment phase, controlled phase, metastatic phase and terminal phase)
Disability-adjusted life year estimationBased on weighted averages of Global Burden of Disease-prescribed weights for Stages I–III and Stage IV34 35Based on Global Burden of Disease-prescribed weights35
Cervical cancer incidenceGlobocan 2020 database of IARC11Globocan 2020 database of IARC11
Cervical cancer mortalityWeighted averages of 5 year stage-specific survival probabilities for untreated and treated cervical cancers (by region) and treatment access proportions (by country)11 21Globocan 2020 database of IARC11
Cervical cancer prevalenceNot applicableGlobocan 2020 database of IARC11
Population sizeUnited Nations World Population Prospects 2019 estimates36United Nations World Population Prospects 2019 estimates combined with time-varying, country-specific probability of death for projected estimates36
Life tablesWorld Health Organization 2019 life tables (constant)37Constructed with United Nations Population Division time-varying, country-specific probability of death36
HPV-16/18 proportionMeta-analysis by IARC32Serrano et al31 based on meta-analysis by IARC32 and retrospective cross-sectional study33
  • HPV, human papillomavirus; IARC, International Agency for Research on Cancer; PRIME, Papillomavirus Rapid Interface for Modelling and Economics.